OPKO Health

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OPKO Health reports robust Q4 performance and outlines growth strategies

OPKO Health's Q4 2022 earnings call highlighted positive performance, innovative strengths, challenges in market positioning, and opportunities for growth and profitability.
The company's focus on product development, operational efficiencies, and strategic clarity underscores a commitment to driving shareholder value and market leadership.
Analyst inquiries and management responses showcased transparency, strategic foresight, and a proactive approach to addressing market dynamics and regulatory challenges.

OPKO Health reports Q1 revenue growth, strategic partnerships with Merck

OPKO Health's Q1 2023 performance reflects revenue growth in Pharmaceuticals but challenges in Diagnostics segment revenue.
Strengths lie in strategic partnerships with Merck, diversified growth initiatives, and cost-saving measures.
Challenges include limited disclosure on NGENLA approval and revenue recognition complexities.
Opportunities exist in new revenue streams, specialty testing expansion, and strategic collaborations for future growth.
Overall, OPKO Health's performance showcases a mix of strengths, challenges, and opportunities for strategic growth and market leadership.

OPKO Health reports improved Q2 performance and growth opportunities

OPKO Health's Q2 2023 performance showed improvements in operating income and revenue despite challenges in the Diagnostics segment.
The company's strategic strengths lie in successful product approvals, collaborations with Merck, and revenue diversification efforts.
While facing challenges such as revenue fluctuations and profitability concerns, OPKO Health is poised for growth with promising opportunities ahead.
Overall, OPKO Health's financial outlook remains positive, with a focus on profitability and expansion through strategic initiatives and partnerships.

OPKO Health excels in Q3 with revenue growth and innovation

OPKO Health's Q3 2023 performance showcased revenue growth, strong product offerings, and strategic advancements in healthcare solutions.
The company's strengths include successful products, cost-cutting measures, and a focus on innovation through collaborations and contracts.
Challenges include the need for more detailed financial disclosures and transparent communication on operational metrics.
Amidst challenges, opportunities for growth through product expansion, partnerships, and operational optimization are key focus areas for OPKO Health.

OPKO Health excels in 2023 with strategic partnerships and growth

OPKO Health demonstrated strong performance in 2023 with key achievements and positive growth in sales and collaborations.
While facing challenges such as revenue decline in the Diagnostics segment, the company is actively addressing them through cost reduction efforts.
Strategic partnerships, financial refinancing, and clear guidance for 2024 position OPKO Health for continued success and growth.

OPKO Health sells assets, expands therapies globally for growth

OPKO Health is strategically streamlining operations and expanding globally.
Despite revenue declines, the company is focused on profitability and growth.
Strong progress in ModeX programs and collaborations for new therapies.
Emphasis on oncology testing and potential partnerships in oncology space.

OPKO Health reports robust Q2 performance and eyes growth opportunities

OPKO Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives for growth, and a focus on operational efficiency and innovation.
The company faces challenges in managing expectations, addressing concerns, and navigating potential acquisitions, but opportunities in collaborations and market expansion are promising.
Overall, OPKO Health's disciplined approach to financial management, clinical development, and strategic partnerships positions it for continued success and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MIAMI, May 24, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced a transfer of the licensed rights to RAYALDEE® in Japan from Japan Tobacco Inc. (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).

OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor

Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in OPKO Health (OPK) Stock?

CYREN

Minerva Neurosciences

Waitr Holdings Inc

Looking for penny stocks to buy during a market correction? Check these 4 out for your watchlist The post Best Penny Stocks to Buy During a Market Correction?

Best Penny Stocks to Buy During a Market Correction? Check These 4 Out

MIAMI, May 07, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) has entered into exchange agreements with certain noteholders of the Company's 4.50% Convertible Senior Notes due 2025 (“Notes”). The noteholders have agreed to exchange $55.42 million of the Company's outstanding 2025 Notes for shares of the Company's common stock.

OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders

OPKO Health's (OPK) first-quarter results benefit from strength in diagnostics.

OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top

OPKO Health, Inc. (OPK) CEO Phillip Frost on Q1 2021 Results - Earnings Call Transcript

OPKO Health (OPK) delivered earnings and revenue surprises of 0.00% and 8.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Meets Q1 Earnings Estimates

Shares of OPKO Health (NASDAQ:OPK) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 155.56% over the past year to $0.05, which were in line with the estimate of $0.05.

OPKO Health: Q1 Earnings Insights

Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

OPKO Health Reports 2021 First Quarter Business Highlights and Financial Results

OPKO Health's (OPK) BioReference expands its major league sports relationships with the announcement of COVID-19 testing agreement with MLB.

OPKO Health's (OPK) BioReference Extends Sports Partnerships

OPKO Health's (OPK) BioReference expands COVID-19 testing in schools to create a safer learning environment for students, teachers, staff and their families.

OPKO Health (OPK) BioReference Extends COVID-19 School Testing

ELMWOOD PARK, N.J., March 26, 2021 /PRNewswire/ --  BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the expansion of its COVID-19 school testing program to support the return to in-person classroom instruction across the country.

BioReference Laboratories Expands COVID-19 School Testing Program

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

OPKO Health (OPK) Down 9.5% Since Last Earnings Report: Can It Rebound?

Athenex

Bellus Health Inc

Catalyst Pharmaceuticals

New Age Beverages

Spectrum Pharma

Uranium Energy

These penny stocks have more than just a low price point. They have Wall Street analysts backing up those prices with high price targets.

7 Penny Stocks That Wall Street Thinks Are Undervalued

LiveXLive Media

Limelight Networks

Nokia

OrganiGram Holdings Inc.

BioDelivery Sciences

These seven penny stocks are most likely to push through the $5 mark having built a significant head of steam in the past year. The post 7 Penny Stocks Close To Busting Through the $5 Mark appeared first on InvestorPlace.

7 Penny Stocks Close To Busting Through the $5 Mark

Agree Realty

Avis Budget Group

Zoetis

American Assets

Incyte

Molecular Templates

Royalty Pharma

Sonos

United States Lime & Minerals, Inc.

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.

The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More

Pfizer

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for somatrogon, a long-acting recombinant human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD). Pfizer expects a decision from the European Commission in 2022. “Today's announcement is

EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

Amarin Corporation Plc

Kelly Services

Skechers U.S.A.

Switch

With the crazy bullishness in the market, you can't find too many discounted plays. However, these sleeper stocks might just give your portfolio the kickstart it needs in 2021.

8 Sleeper Stocks That Could Take Off Soon

NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced its participation in the NY Forward Rapid Testing Program and opened eight locations offering COVID-19 rapid testing around New York. This program is designed to provide...

New York State Partners with BioReference Laboratories to Spearhead the NY Forward COVID-19 Rapid Test Program to Help Reopen the New York Economy

OPKO Health's (OPK) fourth-quarter results benefit from strength in diagnostics.

OPKO Health (OPK) Q4 Earnings and Revenues Beat Estimates

Opko Health Inc (NASDAQ: OPK) reported Q4 results that came in above expectations with EPS of $0.05 beating the estimate of $0.04 and sales of $494.6 million higher than the consensus of $443.1 million. The growth was driven by a more than double increase in service revenues, slightly offset by lower product revenues.

Opko Health's Q4 Service Revenues More Than Double Due To COVID-19 Testing Services

Hint: Investors are more focused on concerns about the future than successes of the recent past.

Here's Why OPKO Health's Solid Q4 Results Didn't Send Shares Flying Higher

OPKO Health, Inc. (OPK) CEO Dr. Phillip Frost on Q4 2020 Results - Earnings Call Transcript

OPKO Health (OPK) delivered earnings and revenue surprises of 25.00% and 13.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Q4 Earnings and Revenues Surpass Estimates

Shares of OPKO Health (NASDAQ:OPK) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 266.67% over the past year to $0.05, which beat the estimate of $0.04.

News for OPKO Health Stock (OPK)